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The focus of this paper is treatment of obesity in relation to the management of hedonic
appetite. Obesity is a complex condition which may be potentiated by excessive reward
seeking in combination with executive functioning deficits that impair cognitive control of
behavior. Stimulant medications address both reward deficiency and enhancemotivation,
as well as suppressing appetite. They have long been recognized to be effective for
treating obesity. However, stimulants can be abused for their euphoric effect. They
induce euphoria via the same neural pathway that underlies their therapeutic effect
in obesity. For this reason they have generally not been endorsed for use in obesity.
Among the stimulants, only phentermine (either alone or in combination with topiramate)
and bupropion (which has stimulant-like properties and is used in combination with
naltrexone), are approved by the United States Food and Drug Administration (FDA)
for obesity, although dexamphetamine and methylpenidate are approved and widely
used for treating attention deficit hyperactivity disorder (ADHD) in adults and children.
Experience gained over many years in the treatment of ADHD demonstrates that with
careful dose titration, stimulants can be used safely. In obesity, improvement in mood
and executive functioning could assist with the lifestyle changes necessary for weight
control, acting synergistically with appetite suppression. The obesity crisis has reached
the stage that strong consideration should be given to adequate utilization of this effective
and inexpensive class of drug.
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INTRODUCTION
The obesity epidemic has been attributed to the easy availability of high energy, palatable foods,
together with an increasingly sedentary lifestyle. The solution to obesity should be a simple matter
of balancing energy intake to requirement, but unfortunately this approach has had limited success
and the prevalence of obesity continues to rise. Treatment of obesity has a cost, but could result in
massive savings via long-term disease prevention.
The costs of obesity include the costs of treating the medical complications, the days of work
missed and disability payments. The three main treatment modalities are lifestyle interventions,
bariatric surgery or medication. A variety of psychological treatments have been trialed for
assisting with making the required lifestyle changes (McElroy et al., 2015a). Success with lifestyle
intervention depends on the individual’s motivation and many cannot sustain the effort (Grodstein
et al., 1996), limiting the cost-effectiveness of this modality. Bariatric surgery has the drawbacks of
expense and surgical complications (Dixon, 2014), with ongoing costs of supplements to prevent
nutritional deficiencies (Lopes et al., 2015). However, it has been calculated that the cost of surgery
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can be offset by savings inmedication costs within 2–7 years, with
those with existing obesity complications having the potential for
the greatest savings (Lopes et al., 2015). Using more complex
modeling, bariatric surgery appears highly cost-effective, with
an average gain of 2.9 years of health at a relatively low cost
of $9000 per year (Michaud et al., 2012). The benefits are
less clear for medication as outcomes can be more variable.
However, pharmacological treatment to help make necessary
lifestyle changes more achievable would appear an attractive
option, particularly if used as an early intervention. This would
potentially involve more treatment-years and result in more
modest benefits to a greater number of people. The cost-
effectiveness of such treatment would be highly dependent on
the cost of the drug. The cost of developing a new drug has been
estimated at $2.6 billion (Avorn, 2015), which has to be recovered
before the patent expires. This gives a substantial economic
advantage to generic prescribing of older drugs.
One main target of pharmacotherapy is appetite suppression.
Appetite control may be considered to have two components;
homeostatic and hedonic. The homeostatic component has
the essential function to maintain daily energy requirement
for sustaining bodily functions such as body temperature,
circulation, breathing, and the energy required for movement.
Gut hormones like cholecystokinin, ghrelin, glucagon-like
peptide-1, and peptide YY regulate the inclination to feed,
having an immediate effect on sensations of hunger or satiety
(Cummings and Overduin, 2007). Leptin reflects fat mass and
acts over a longer time-frame to suppress the appetite as fat stores
increase (Saad et al., 1998). Insulin, glucagon-like peptide-1, and
cortisol have a regulatory role in energy balance and utilization
(Osto et al., 2007). The hormonal homeostatic mechanisms
adjust in response to weight loss with changes that increase the
appetite and promote weight regain (Sumithran et al., 2011).
However, eating is not simply a matter of meeting daily energy
requirements but is also associated with pleasure. This leads to
an additional hedonic drive to eat.
HEDONIC APPETITE
Hedonic appetite may be considered as a continuum, extending
from the normal situation of individuals enjoying some foods
more than others, through comfort eating whichmay occur when
the mood is low, to the final extreme situation in which an
individual appears to be addicted to food as to a drug of addiction.
NEURAL MECHANISMS
Reward Mechanisms
The hedonic component of appetite ismediated by central reward
mechanisms and has the ability to override homeostatic satiety
mechanisms (Volkow et al., 2008). The enjoyment associated
with eating is attributed to activation of the dopamine mediated
reward pathway in the limbic region of the brain (Wang
et al., 2009; DiLeone et al., 2012). The endocannabinoid and
opioid systems are also involved in central appetite control,
relating to food palatability, and interacting with mesolimbic
reward pathway and reinforcing the motivation for food seeking
(Volkow et al., 2008). The mesolimbic pathway communicates
with the nucleus accumbens, which is involved in reward and
appetite control. Wang et al. have shown reduced dopamine D2
receptor density in individuals with obesity (Wang et al., 2001).
Although the resulting decreased dopaminergic activity could
explain vulnerability to obesity, such that more food is required
to obtain satisfaction (D’Addario et al., 2014), overeating of
palatable food may itself lead to a reduction in the D2 receptors
and promote compulsive eating (DiLeone et al., 2012). This
suggests that a blunting of the rewardmechanisms and associated
desire for highly palatable food may be both a cause and a
consequence of obesity. A similar situation pertains with drugs
of abuse which may initially be taken for pleasure, subsequently
progressing to craving, and diminished satisfaction due to
desensitization of the reward mechanisms (Volkow et al., 2008).
In each case the repetition leads to similar changes in the reward
circuitry and associated reductions in the experience of pleasure
for other activities, together with conditioning to stimulus related
cues and compulsive consumption (Kenny et al., 2013).
The above mechanisms suggest that the enjoyment of
palatable food may be pursued to excess, ultimately developing
into a self-perpetuating cycle of craving and compulsive eating
that is independent of hunger and which may manifest as
binge eating (Ziauddeen et al., 2012; Gautron et al., 2015).
This end-point may have contributing factors such as individual
susceptibility (perhaps associated with low D2 receptors) and
environmental factors (such as food availability) and lack of
enjoyment or reward from other facets of life. An observational
study showing that individuals who suffer from obesity may be
prone to addiction (Reslan et al., 2014) supports the notion of
a common susceptibility. The idea of obesity as an addiction
is not new. The German word for obesity is “fettsucht” or
“fat addiction.” Of course, putative food addiction differs from
addiction to drugs as food is essential to life and there is no
chemical withdrawal syndrome (Ziauddeen et al., 2012).
Although eating excessively for pleasure may progress to
dissatisfaction, craving, and possible food addiction, this does
not always happen. It has been suggested that some individuals
may have under activity of their intrinsic reward mechanisms,
resulting in reward seeking behavior that can be excessive
and maladaptive. This has been termed reward deficiency
syndrome (Downs et al., 2013). Dissatisfaction associated with
a state of reward deficiency could be associated with low
mood, which the individual might address with comfort eating.
This could underpin the known association of obesity with
depression (Dawes et al., 2016). This process could occur at
a subtle level, with imperceptible discrepancies in the balance
between energy intake and utilization over time leading to
obesity.
This sensation of reward associated with food and other
pleasurable stimuli is important for motivating animals to fulfill
the basic functions that are necessary for the survival of the
individual and the species. At a more subtle level, experiencing
adequate satisfaction in the daily tasks of life helps to maintain
a positive mood and outlook (Catalino and Fredrickson, 2011).
Therefore, eating may be a strategy for mood regulation, with
food restriction resulting in irritability.
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Executive Functions
Excessive hedonic appetite may be overcome by the executive
functions of the prefrontal cortex exerting behavioral control for
curbing disinhibited eating. This requires consistent motivation.
Individuals lacking sufficient executive control may find it harder
to combat obesity, due to their greater difficulty in making
decisions that involve delaying gratification (Davis et al., 2010).
This has been supported by a study that showed lower levels of
activation of the prefrontal cortex in response to food in obese
non-dieters when compared to successful dieters (DelParigi et al.,
2007). Individuals with obesity could therefore be excessively
reward seeking and they could also have deficits in the executive
functions associated with motivation and cognitive control of
behavior. However, as with the reward mechanisms, obesity
can itself lead to impaired executive functioning and behavioral
control. One obvious manifestation of this is in the repeated
relapses that may follow well-reasoned decisions to keep to a diet
(Volkow et al., 2016).
Similar reward and executive functioning deficits also typify
ADHD (Poulton and Nanan, 2014), perhaps the main difference
being that in obesity the reward seeking and executive
functioning deficits, such as impulsive behavior and poor
motivation, result in excessive food intake. In both conditions
these two types of predisposing deficit would be summative in
their effects.
IMPLICATIONS FOR
THERAPY—STIMULANTS
If an important biological mechanism is deficient to the
extent that health is compromised, it is logical to try to
treat the deficiency medically, targeting the pathways involved.
Stimulants activate reward mechanisms by interacting with
amine transporter systems, decreasing the synaptic reuptake
of dopamine and noradrenaline (Madras et al., 2005), and to
a lesser extent serotonin (Kuczenski and Segal, 1997) so that
neurotransmission is enhanced. This results in mundane tasks
appearing more rewarding (Volkow et al., 2004). Stimulants
are also associated with appetite suppression, which correlates
with the increased activity of the mesolimbic reward pathway
and elevated extracellular dopamine the nucleus accumbens
(Rowley et al., 2000). Therefore, stimulants address the reward
deficit, which may rectify the compulsion to eat excessively
and could also explain their positive effect on mood (Martin
et al., 1971). However, stimulants have the additional effect
of a dose-related improvement in executive functioning, hence
their value in ADHD. It has been shown with methylphenidate
that this improvement rises to a maximum and then declines
once the optimal dose has been exceeded (Gamo et al., 2010).
When treated with stimulants, children with ADHD are able
to concentrate more consistently and are more efficient at task
completion (MTA Cooperative Group, 1999). They are also more
able to think rationally and consider the consequences of their
actions.
The ability of the stimulants to target both the reward
deficiency and the executive functioning deficits suggests
that they are a logical treatment for obesity. At higher
doses stimulants are associated with adverse effects on
mood, progressing to nervousness, depression and emotional
irritability, with reversible paranoia, and psychosis developing
with further dose increases (Griffith et al., 1972). Stimulants are
also associated with elevations in heart rate and blood pressure
due to their sympathomimetic effects, which limits their use
in individuals with cardiovascular disease (Stiefel and Besag,
2010). The practice of dose titration to maximize behavioral
improvement and minimize adverse effects may explain their
safety record in the treatment of ADHD (Merkel, 2010).
Although under activity of the reward pathway can lead
to dissatisfaction and low mood, too much stimulation can
be addictive and stimulants are recognized as drugs of abuse.
The ability of stimulants to increase extracellular dopamine
correlates not only with their therapeutic effect in ADHD
and obesity but also with their ability to induce euphoria,
which can be addictive (Volkow and Swanson, 2003). The
reinforcing sensation of euphoria correlates with a rapid rate
of dopamine receptor occupancy. As euphoria is dependent
on the rate of absorption rather than the actual dose of
stimulant, a dose of methylphenidate that might be therapeutic
for oral administration, when given intranasally can produce
euphoria comparable to that obtained using cocaine (Volkow and
Swanson, 2003). Among the stimulants, methamphetamine is the
most addictive as it rapidly accumulates in the brain, inducing
euphoria even when taken orally (Fowler et al., 2008).
The first stimulant to be endorsed by the FDA for the
treatment of obesity was methamphetamine in 1947 (United
States Food and Drug Administration, 2012). In the 1950s and
1960s dexamphetamine was widely prescribed for a range of
problems including obesity, depression, and poor motivation
(Kiloh and Brandon, 1962). Although it was recognized that it
might occasionally be taken as a habit to restore confidence it was
generally considered safe even for long-term use (Editorial, BMJ,
1955). However, it came to light that some people were abusing
dexamphetamine and had been fraudulently obtaining multiple
prescriptions and having them dispensed by different pharmacies
(Kiloh and Brandon, 1962). A few were admitted to hospital
with psychosis and malnutrition, experiencing depression on
drug withdrawal. Then the opinion suddenly turned against
the stimulants for the treatment of obesity (United States Food
and Drug Administration, 2012). Despite this, the stimulant
phentermine has continued to be licensed for short term use in
obesity and in combination with the anticonvulsant topiramate
for long term use. Furthermore, bupropion, a drug used for
treating depression and nicotine addiction, which has many
similarities to the stimulants in its clinical effects, was licensed
for treatment of obesity in combination with naltrexone in 2014
(United States Food and Drug Administration, 2014). Therefore,
despite a widespread view that the use of stimulants for obesity
is inappropriate, medications that appear remarkably similar in
their effects and in their abuse potential are still being used. The
use of the opiates for pain relief demonstrates that drugs that
are highly addictive can be used therapeutically provided there
are adequate safeguards. Similarly, the stimulants have continued
to be prescribed for individuals with ADHD, a condition with
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recognized susceptibility to risky behavior including substance
abuse (Molina et al., 2013).
The two main arguments against the stimulants is their
abuse potential and their apparent loss of efficacy with time,
once a new steady state has been reached after the initial
weight loss. For example, the effect that stimulants have for
enhancing reward could lead to inappropriate use, or potentiate
addictive behavior or compulsions such as binge eating. However,
lisdexamfetamine, a pro-drug for dexamphetamine, has been
shown to be effective for reducing binge eating (McElroy et al.,
2015b). Oral administration also reduces the risk as it limits
the potential for euphoria and increases the probability of
adverse gastrointestinal side effects such as nausea and fullness,
which might be exacerbated by eating (DiLeone et al., 2012).
Furthermore, stimulants are not associated with a physical
withdrawal syndrome that promotes continuous use. Although
stimulant abuse is a particular concern for people with risk
factors for addiction, one very important distinction between
individuals with obesity and those who have abused drugs is that
food addiction does not involve any illegal activity. Therefore,
such people could have strong reservations for using illegal or
dishonest means for acquiring drugs.
When considering the advantages and disadvantages of the
stimulants as outlined above, we consider the most appropriate
way to use the stimulants in obesity would be to prescribe for
a restricted period only, focusing on the beneficial effects on
mood and motivation while establishing the lifestyle changes
necessary for weight control, rather than encouraging reliance on
the appetite suppression. This would also limit the potential for
abuse and adverse long-term cardiovascular effects.
PSYCHOTROPIC EFFECTS OF DRUGS
DEVELOPED FOR OBESITY
Drugs that target hedonic appetite often have actions comparable
to the stimulants on mood, motivation, and blood pressure,
suggesting a comparable mode of action (Table 1). However, the
beneficial psychotropic effects have generally been neglected and
instead of dose optimization, studies have tended to randomize
participants to fixed doses of active drug or placebo (Munro et al.,
1968; Astrup et al., 2008). This methodology means that for some
the dose will be too low, while others may have adverse effects
on mood due to the dose being excessive. Poor understanding of
the need for individual dose titration has resulted in drugs being
attributed adverse psychiatric side effects. Given the complexities
of the actions of these drugs and their varying affinities for the
different neurotransmitter systems, the most practical way to
determine the correct dose is by titration to the clinical effects.
Titration works well in ADHD where the aim is to improve
the functional deficits. Even in obesity there is often scope for
improvement in mood and motivation and in our research
we have found dose titration possible using adverse effects on
mood as an indication for dose reduction (Poulton et al., 2015).
Therefore, with correct use the psychotropic effects could have
the potential to assist with the lifestyle changes that are vital for
weight control. It is important for physicians to understand how
best to use these medications (Fujioka, 2015).
Phentermine-Topiramate
Phentermine has similarities with dexamphetamine in that at
low dose a beneficial effect on mood has been observed while
higher doses can induce hostility and anger (Brauer et al.,
1996). It may be inferred that phentermine, as a stimulant,
will lead to dose-related improvements in executive functioning
(Gamo et al., 2010) and it has been used effectively for treating
ADHD (Rothman, 1996). Although phentermine is considered
less addictive than dexamphetamine (Griffiths et al., 1978), it is
important to compare its effects at bioequivalent doses. Animal
studies have shown that phentermine and dexamphetamine
at equipotent doses for appetite suppression are associated
with comparable levels of dopamine elevation in the nucleus
accumbens (Rowley et al., 2000). Phentermine is generally
used in a fixed dose regimen (Munro et al., 1968). It is now
available in America in combination with topiramate (United
States Food and Drug Administration, 2012; Alfaris et al., 2015)
although marketing authority for this combination (Qsymia)
was refused by the European Medicines Agency (European
Medicines Agency, 2013). This combination uses lower doses
of each drug than would be used with either drug given as
monotherapy (Alfaris et al., 2015; British National Formulary,
2015). Phentermine is still available in the United Kingdom but
is not officially recommended for use in obesity (Kumar and
Aronne, 2015).
Topiramate is an anticonvulsant and is associated with
sedation and dose related cognitive impairment, causing
difficulties with memory and concentration at higher doses (Bray
et al., 2003). At low dose it can lead to improvement in mood
disorders but at higher doses can be associated with depression,
aggression, and psychosis (Besag, 2004). Its mode of action in
obesity is unclear, although there may be scope for dose titration
to maximize the favorable effect on mood.
Bupropion-Naltrexone
Bupropion is classified as a substituted cathinone, a class
of drug that acts as a central nervous system stimulant as
it increases the synaptic concentrations of catecholamines
by inhibiting reuptake and enhancing their release (Paillet-
Loilier et al., 2014). Experimentally in mice bupropion has
a similar profile of dopamine related behavioral effects to
methamphetamine, being rewarding (reinforcing) at lower doses
and causing hyperlocomotion at higher doses (Mori et al.,
2013). Interestingly, a study using bupropion for treating obesity
documented weight loss with minimal effects on mood or
behavior (Anderson et al., 2002), suggesting a low risk of
adverse psychotropic effects. Bupropion can improve executive
functioning (working memory and sustained attention; Perkins
et al., 2013) and has been used for treating ADHD with
comparable efficacy to methylphenidate. It has abuse potential,
particularly when taken intranasally (Hilliard et al., 2013) and can
cause a reversible psychosis (Javelot et al., 2010).
Bupropion is used for obesity in combination with naltrexone
(Greenway et al., 2009) a mu opioid receptor antagonist that
is used in the treatment of addiction to a range of substances
including opiates, nicotine, alcohol and amphetamines as
it reduces craving (Woody, 2014). Both bupropion and
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TABLE 1 | Drugs that are approved or have been trialed for the treatment of obesity and their psychotropic effects.
Mechanism Drug Approved for
obesity, either
alone, or in
combination
Favourable
psychotropic effects
Unfavourable
psychotropic effects
Euphoria
or
addiction
1. PREVENTING NUTRIENT ABSORPTION
Lipase inhibitor Orlistat Yes No No
2. HOMEOSTASIS: ENERGY AND CARBOHYDRATE BALANCE
Glucagon-like peptide-1
analog
Liraglutide Yes No No
3. CENTRAL EFFECTS
Potentiating catecholamines
(blocking reuptake,
enhancing release)
Stimulants:
Phentermine
Dexamphetamine
Yes
No
Improvements in
executive functioning,
mood elevation,
increased vigor/activity
Anger/hostility,
depression, paranoia,
hyperlocomotion,
psychosis
Yes
Bupropion Yes Improvements in
executive functioning
Hyperlocomotion
psychosis
Yes
Tesofensine No Mood elevation,
increased vigor/activity
Anger/hostility
Selective serotonin 2C
receptor agonist
Lorcaserin Yes Reduces impulsive
behavior
Fatigue, depression,
cognitive impairment
Cannibinoid type 1 receptor
blocker
Rimonabant
Taranabant
No
No
Increased vigor/activity Anger/hostility, anxiety,
depression, suicide risk
Mu-opioid receptor
antagonist
Naltrexone Yes Reduces craving
Anticonvulsant: mechanism
of action in obesity unclear
Topiramate Yes Mood improvement Sedation, cognitive
impairment,
depression,
aggression, psychosis
The psychotropic effects may be managed by appropriate dosage adjustments.
naltrexone are associated with weight loss and together their
effects appear to be synergistic (Greenway et al., 2009). This
combination (Contrave) was approved by the FDA for chronic
weight management in 2014 (United States Food and Drug
Administration, 2014).
Tesofensine
Tesofensine is a drug that showed efficacy but was abandoned
because it caused hypertension (Astrup et al., 2008). Like the
stimulants, it blocks the reuptake of dopamine, noradrenaline,
and serotonin. Effects on behavior and mood were noted in
phase-II studies, with increased activity at all doses and mood
changes, particularly at higher doses, including mood elevation
and also anger and hostility. That these effects are likely to be
dopaminergic is supported by positron emission tomography
showing blockade of the dopamine transporter leading to up-
regulation of the dopamine pathway (Appel et al., 2014). It can be
speculated that as elevated blood pressure was predictable from
its mode of action, this might have been managed with lower
doses and a more flexible dosing regimen.
Cannibinoid Type 1 Receptor Blockers
Rimonabant and Taranabant
Rimobanant initially appeared promising as a treatment for
obesity as it was associated with improvement in cardiometabolic
risk factors that appeared to be in excess of the improvement
expected for the degree of weight loss (Nissen et al., 2008).
Despite the psychiatric side effects of mood alteration, the drug
was approved and marketed. However, once it was being used
in greater numbers an association with suicide was observed
and all trials were terminated (Topol et al., 2010; McElroy et al.,
2015c).
Taranabant is closely related to rimonabant. When
rimonabant was withdrawn, all further development of
taranabant was terminated (Aronne et al., 2010). In phase-II
trials that involved randomization to fixed doses of drug it was
noted that psychiatric side effects were the commonest reason
for study attrition (Proietto et al., 2010). Anger and hostility
were seen at all doses. At the lowest dose there was increased
vigor-activity; depression-dejection was seen on the highest dose.
These apparently dopaminergic effects may be due to synergy
of the dopamine and endocannibinoid pathway (Despres et al.,
2005).
CONCLUSIONS
Physicians treating obesity need to understand and appreciate
the psychotropic properties of anorexigenic medications, so that
treatment can be optimized. The psychiatric side effects that
have plagued many efficacy studies might actually be evidence
of their mode of action and therefore their efficacy (Astrup
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et al., 2008; Proietto et al., 2010). This misclassification of
the associations of therapeutic efficacy may be sabotaging an
important line of drug development. The potential for abuse of
drugs with dopaminergic effects is a serious concern but does
not preclude their use in ADHD. Indeed there is no clearly
apparent logical reason why dexamphetamine is used for treating
ADHD while phentermine has been retained for obesity, which
raises the question of whether this was simply an accident of
history. Ongoing research in our group is examining the effects
of dexamphetamine for treating obesity (Poulton et al., 2015).
We suggest that the prejudice against the stimulants for treating
obesity is perhaps misplaced and favors surgery and new drug
development. Meanwhile, in the absence of cheap, effective and
accessible treatments the obesity epidemic shows little sign of
abating.
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